Just a little sneak peak of our booth set up at @SABCSSanAntonio. The Epic Sciences Biopharma team looks forward to discussing how our technology can inform your clinical development efforts. Visit us 12/7 to 12/9 from 10-5 at booth #529. We look forward to seeing you there.
We are excited to announce William J. Kullback as CFO of Epic Sciences.
Bill’s experience navigating companies through successful expansion and his background in mergers & acquisitions will be critical as Epic moves into the next phase of company growth.
https://t.co/pEu1YsHAyi
Epic Sciences will be participating in #PODC2022 in Chicago on October 19th & 20th.
We look forward to meeting with collaborators and new potential partners as we all work together to improve care for patients with #cancer.
https://t.co/KvOdhy6vly #oncology#clinicaltrials
Listen to the latest @Breastfriends podcast to learn about the numerous obstacles that still remain for patients and clinicians who are battling metastatic breast cancer.
Tune in to the Breast Friends YouTube Channel here: https://t.co/w6hcnwAL7z
Great collaboration at the recent #WorldADC conference in San Diego as antibody-drug conjugates gain momentum! CTC-based #liquidbiopsy HER2, TROP2, PSMA, HER3, & Claudin18.2 protein expression can add insights for #ADC development.
To learn more, email us at [email protected]
Liquid biopsies offer the opportunity to gather information about each patient’s evolving cancer more frequently. Check out "The Impact of PSMA+ CTCs in Men with mCRPC" presented at #ESMO2022.
Visit our website to learn more: https://t.co/VuCuT2ysym #prostatecancer#liquidbiopsy
Pleased to share our latest analysis of PROPHECY showing the independent prognostic importance of PSMA+ CTCs in men with mCRPC treated with Abi/Enza. Sets stage for testing in context of PSMA therapy @DukeGUCancer@EpicSciences@EAntonarakis@ThePCCTC@Daniel_J_George
President & CEO of Epic Sciences supporting our 2022 Komen San Diego More Than Pink Walk by serving on the Susan G. Komen Executive Leadership Committee. https://t.co/p3kvfEzUAZ
We look forward to connecting with our partners at the @World_ADC Conference in San Diego, September 6-9!
These are exciting times to be working with partners developing new ADCs that will benefit patients! #WorldADC#biomarkers#cancer#drugdevelopment
Lots of buzz re: PSMA-PET, LuPSMA and biomarkers at #ASCO22.. Our work of serial CTC profiling of PRINCE trial (LuPSMA+pembro): assoc with PET metrics and early change/clearance of PSMA+ CTCs may forecast outcome on LuPSMA 1/2 @DrMHofman@SandhuShahneen@PeterMacRes@EpicSciences
Congratulations, @EpicSciences! The biotech company has raised $43M to advance its liquid biopsy offerings 🥳
Its #SDlifechanging tests are intended to be used when tissue biopsy is inaccessible or infeasible.
P.S. They're hiring 👀
https://t.co/zkHQoZ3eqe
“We are continuing to innovate testing for both the research and clinical markets”- Lloyd Sanders, president and CEO of @EpicSciences – as quoted in last week’s @SDBusiness article covering Epic’s recent #funding announcement. https://t.co/SLvBychDzu #liquidbiopsy#diagnostics
Did you happen to see @EpicSciences featured on the @Nasdaq MarketSite in NY Time Square last week? It’s exciting to have world-class investors that are committed to truly partnering with Epic and is a privilege to work with them to invest in improving care for cancer patients.